

# **Levamisole Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 2.2 24.01.2024 9081923-00007 Date of first issue: 21.07.2021

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Levamisole Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub- : Veterinary product

stance/Mixture

Recommended restrictions

on use

Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD

20 Spartan Road

1619 Spartan, South Africa

Telephone : +27119239300

E-mail address of person

responsible for the SDS

EHSDATASTEWARD@msd.com

## 1.4 Emergency telephone number

+1-908-423-6000

# **SECTION 2: Hazards identification**

## 2.1 Classification of the substance or mixture

### Classification (REGULATION (EC) No 1272/2008)

Acute toxicity, Category 4 H302: Harmful if swallowed.

Reproductive toxicity, Category 2

H361d: Suspected of damaging the unborn child.

Specific target organ toxicity - repeated

H373: May cause damage to organs through pro-

exposure, Category 2 longed or repeated exposure.

#### 2.2 Label elements

## Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :

<u>\( \) \( \) \( \) \( \)</u>

Signal word : Warning

Hazard statements : H302 Harmful if swallowed.

H361d Suspected of damaging the unborn child.

H373 May cause damage to organs through prolonged or

repeated exposure.



## Levamisole Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 2.2 24.01.2024 9081923-00007 Date of first issue: 21.07.2021

Precautionary statements : Prevention:

P201 Obtain special instructions before use.

P260 Do not breathe dust.

P270 Do not eat, drink or smoke when using this product. P280 Wear protective gloves/ protective clothing/ eye protec-

tion/ face protection.

Response:

P301 + P312 + P330 IF SWALLOWED: Call a POISON

CENTER/ doctor if you feel unwell. Rinse mouth.

P308 + P313 IF exposed or concerned: Get medical advice/

attention.

Hazardous components which must be listed on the label:

levamisole hydrochloride

#### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form combustible dust concentrations in air during processing, handling or other means.

### **SECTION 3: Composition/information on ingredients**

#### 3.2 Mixtures

#### Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
levamisole hydrochloride	16595-80-5 240-654-6	Acute Tox. 3; H301 Repr. 2; H361d STOT RE 2; H373 (Blood, Testis) Aquatic Chronic 3; H412	>= 10 - < 20

For explanation of abbreviations see section 16.

### **SECTION 4: First aid measures**

### 4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection,



## Levamisole Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.2
 24.01.2024
 9081923-00007
 Date of first issue: 21.07.2021

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

Never give anything by mouth to an unconscious person.

#### 4.2 Most important symptoms and effects, both acute and delayed

Risks : Harmful if swallowed.

Suspected of damaging the unborn child.

May cause damage to organs through prolonged or repeated

exposure.

Contact with dust can cause mechanical irritation or drying of

the skin.

Dust contact with the eyes can lead to mechanical irritation.

### 4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

# **SECTION 5: Firefighting measures**

## 5.1 Extinguishing media

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

### 5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.





Version Revision Date: SDS Number: Date of last issue: 30.09.2023 2.2 24.01.2024 9081923-00007 Date of first issue: 21.07.2021

Hazardous combustion prod- :

ucts

Carbon oxides

5.3 Advice for firefighters

Special protective equipment:

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

Evacuate area.

#### **SECTION 6: Accidental release measures**

### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

#### 6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

## 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable con-

tainer for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

#### **SECTION 7: Handling and storage**

## 7.1 Precautions for safe handling

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.



## Levamisole Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.2
 24.01.2024
 9081923-00007
 Date of first issue: 21.07.2021

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation Advice on safe handling Use only with adequate ventilation.

Do not breathe dust.

Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

#### 7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

Keep in properly labelled containers. Store locked up. Store in

accordance with the particular national regulations.

Advice on common storage : Do not store with the following product types:

Strong oxidizing agents

7.3 Specific end use(s)

Specific use(s) : No data available

### **SECTION 8: Exposure controls/personal protection**

#### 8.1 Control parameters

#### **Occupational Exposure Limits**

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis	
levamisole hydro- chloride	16595-80-5	TWA	20 μg/m3 (OEB 3)	Internal	
	Further information: Skin				
		Wipe limit	200 μg/100 cm <sup>2</sup>	Internal	



## Levamisole Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 2.2 24.01.2024 9081923-00007 Date of first issue: 21.07.2021

#### 8.2 Exposure controls

#### **Engineering measures**

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

#### Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable

suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Filter type : Particulates type (P)

#### **SECTION 9: Physical and chemical properties**

## 9.1 Information on basic physical and chemical properties

Appearance : powder Colour : white

Odour : No data available Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling :

range

No data available

Flash point : Not applicable

Evaporation rate : Not applicable

Flammability (solid, gas) : May form combustible dust concentrations in air during pro-

cessing, handling or other means.

Upper explosion limit / Upper : No data available



## Levamisole Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 2.2 24.01.2024 9081923-00007 Date of first issue: 21.07.2021

flammability limit

Lower explosion limit / Lower :

flammability limit

No data available

Vapour pressure : Not applicable

Relative vapour density : Not applicable

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility
Partition coefficient: n-

octanol/water

No data available

Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

9.2 Other information

Molecular weight : No data available

Particle size : No data available

## **SECTION 10: Stability and reactivity**

#### 10.1 Reactivity

Not classified as a reactivity hazard.

### 10.2 Chemical stability

Stable under normal conditions.

### 10.3 Possibility of hazardous reactions

Hazardous reactions : May form combustible dust concentrations in air during pro-

cessing, handling or other means. Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents



# **Levamisole Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 2.2 24.01.2024 9081923-00007 Date of first issue: 21.07.2021

## 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

## **SECTION 11: Toxicological information**

## 11.1 Information on toxicological effects

Information on likely routes of:

exposure

Inhalation

Skin contact Ingestion

Eye contact

**Acute toxicity** 

Harmful if swallowed.

**Product:** 

Acute oral toxicity : Acute toxicity estimate: 1.200 mg/kg

Method: Calculation method

**Components:** 

levamisole hydrochloride:

Acute oral toxicity : LD50 (Rat): 180 mg/kg

LD50 (Mouse): 223 mg/kg

LD50 (Rabbit): 458 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Skin corrosion/irritation

Not classified based on available information.

**Components:** 

levamisole hydrochloride:

Remarks : No data available

Serious eye damage/eye irritation

Not classified based on available information.

**Components:** 

levamisole hydrochloride:

Remarks : No data available

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.



## Levamisole Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.2
 24.01.2024
 9081923-00007
 Date of first issue: 21.07.2021

### Respiratory sensitisation

Not classified based on available information.

#### **Components:**

## levamisole hydrochloride:

Remarks : No data available

#### Germ cell mutagenicity

Not classified based on available information.

## **Components:**

### levamisole hydrochloride:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

### Carcinogenicity

Not classified based on available information.

#### **Components:**

### levamisole hydrochloride:

Species : Mouse Application Route : Oral Exposure time : 2 Years

NOAEL : 80 mg/kg body weight

Remarks : No significant adverse effects were reported

Species : Rat
Application Route : Oral
Exposure time : 2 Years

NOAEL : 40 mg/kg body weight

Remarks : No significant adverse effects were reported

#### Reproductive toxicity

Suspected of damaging the unborn child.

### **Components:**

#### levamisole hydrochloride:

Effects on fertility : Test Type: Three-generation reproduction toxicity study

Species: Rat

Application Route: Oral

Result: No significant adverse effects were reported

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Oral

Developmental Toxicity: NOAEL: 20 mg/kg body weight

Result: Fetotoxicity



## Levamisole Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 2.2 24.01.2024 9081923-00007 Date of first issue: 21.07.2021

Test Type: Embryo-foetal development

Species: Rabbit Application Route: Oral

Developmental Toxicity: LOAEL: 40 mg/kg body weight

Result: Fetotoxicity

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on development, based on

animal experiments.

### STOT - single exposure

Not classified based on available information.

#### STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

#### **Components:**

### levamisole hydrochloride:

Target Organs : Blood, Testis

Assessment : May cause damage to organs through prolonged or repeated

exposure.

## Repeated dose toxicity

### **Components:**

## levamisole hydrochloride:

Species : Rat
NOAEL : 2,5 mg/kg
Application Route : Oral
Exposure time : 18 Months
Target Organs : Testis

Species : Dog
LOAEL : 20 mg/kg
Application Route : Oral
Exposure time : 18 Months
Target Organs : Blood

Species : Dog LOAEL : 40 mg/kg Application Route : Oral Exposure time : 3 Months

### **Aspiration toxicity**

Not classified based on available information.

## Experience with human exposure

### **Components:**

### levamisole hydrochloride:

Ingestion : Symptoms: Nausea, Vomiting, Headache, Dizziness, hypo-

tension

# **Levamisole Formulation**



Version Revision Date: SDS Number: Date of last issue: 30.09.2023 2.2 24.01.2024 9081923-00007 Date of first issue: 21.07.2021

## **SECTION 12: Ecological information**

### 12.1 Toxicity

### **Components:**

levamisole hydrochloride:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): 37,3 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 64 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

#### 12.2 Persistence and degradability

No data available

#### 12.3 Bioaccumulative potential

No data available

### 12.4 Mobility in soil

No data available

#### 12.5 Results of PBT and vPvB assessment

## **Product:**

Assessment : This substance/mixture contains no components considered

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

0.1% or higher.

#### 12.6 Other adverse effects

#### **Product:**

Endocrine disrupting poten-

tial

The substance/mixture does not contain components considered to have endering disrupting properties according to

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

#### **SECTION 13: Disposal considerations**

#### 13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.



## Levamisole Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.2
 24.01.2024
 9081923-00007
 Date of first issue: 21.07.2021

If not otherwise specified: Dispose of as unused product.

### **SECTION 14: Transport information**

#### 14.1 UN number

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.2 UN proper shipping name

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.3 Transport hazard class(es)

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.4 Packing group

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA (Cargo) : Not regulated as a dangerous good
IATA (Passenger) : Not regulated as a dangerous good

# 14.5 Environmental hazards

Not regulated as a dangerous good

#### 14.6 Special precautions for user

Not applicable

## 14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.



## **Levamisole Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 2.2 24.01.2024 9081923-00007 Date of first issue: 21.07.2021

# **SECTION 15: Regulatory information**

#### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:

AICS :

DSL :

IECSC :

### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

#### **SECTION 16: Other information**

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.

#### **Full text of H-Statements**

H301 : Toxic if swallowed.

H361d : Suspected of damaging the unborn child.

H373 : May cause damage to organs through prolonged or repeated

exposure if swallowed.

H412 : Harmful to aquatic life with long lasting effects.

#### Full text of other abbreviations

Acute Tox. : Acute toxicity

Aquatic Chronic : Long-term (chronic) aquatic hazard

Repr. : Reproductive toxicity

STOT RE : Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways: ADR - Agreement concerning the International Carriage of Dangerous Goods by Road: AIIC - Australian Inventory of Industrial Chemicals: ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - Interna-



## Levamisole Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.2
 24.01.2024
 9081923-00007
 Date of first issue: 21.07.2021

tional Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

#### **Further information**

Sources of key data used to compile the Safety Data
Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

#### Classification of the mixture:

### Classification procedure:

Acute Tox. 4 H302 Calculation method Repr. 2 H361d Calculation method STOT RE 2 H373 Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ZA / EN